Back to search
FDAFDA · Food and drugs·Recall number Z-2460-2026

directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2

Published June 24, 2026 · Recall initiated: April 30, 2026

Summary

FDA records medical device Class II recall Z-2460-2026, published June 24, 2026 and initiated April 30, 2026. Recalling firm: Accriva Diagnostics, Inc.; Status: Ongoing; Reported quantity: 6060; Lot: Lot #: A6DLA001 Unique Device Identifier: 10711234170373. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Assayed Whole blood control contains labeling with incorrect performance range.

What to do

Voluntary: Firm initiated

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Accriva Diagnostics, Inc.
Distributor
Worldwide - US Nationwide distribution including in the states of AL, AR, AZ, CA, FL, GA, ID, IL, IN, KY, MA, MD, MI, MN, MO, MT, NC, NJ, NM, NY, OH, OK, PA, SC, TN, TX, VA, VT, WA, WI, WV and the countries of Canada, Hong Kong, Spain.
Lot
Lot #: A6DLA001 Unique Device Identifier: 10711234170373
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2 recalled?

Yes. FDA published recall Z-2460-2026 on June 24, 2026. Reported hazard: Assayed Whole blood control contains labeling with incorrect performance range.

What should I do if I have this product?

Voluntary: Firm initiated